Plus Therapeutics (PSTV)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 3.870
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 23.425
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Plus Therapeutics Analyst Rating
View moreForecast & Rating
Jul 1, 2026Price forecast
$36.00830.23%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- businessinsider · Aug 17 at 12:16 AM
Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook
- Unusual Whales · Aug 14 at 03:17 PM
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
- PUBT · Aug 14 at 03:16 PM
Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million
- PUBT · Aug 4 at 04:34 PM
Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome
- PUBT · Jul 31 at 07:32 AM
Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3
- StockTitan · Jul 30 at 11:30 PM
Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock News
